|
1-20 (of 41 results)
| Most recent content
(23 Oct 2008):
|
Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
The CAMMS223 Trial Investigators
Abstract |
FREE Full Text |
PDF |
CME Exam
N Engl J Med 2008;
359:1786-1801, Oct 23, 2008.
Original Articles
Multiple Lessons for Multiple Sclerosis
Hauser S. L.
Extract |
Full Text |
PDF
N Engl J Med 2008;
359:1838-1841, Oct 23, 2008.
Editorials
| Earlier content
(since Nov 1997):
|
Focus on Research: The B Cell Old Player, New Position on the Team
McFarland H. F.
Extract |
Full Text |
PDF
N Engl J Med 2008;
358:664-665, Feb 14, 2008.
Perspective
B-Cell Depletion with Rituximab in RelapsingRemitting Multiple Sclerosis
Hauser S. L., Waubant E., Arnold D. L., Vollmer T., Antel J., Fox R. J., Bar-Or A., Panzara M., Sarkar N., Agarwal S., Langer-Gould A., Smith C. H., the HERMES Trial Group
Abstract |
FREE Full Text |
PDF
N Engl J Med 2008;
358:676-688, Feb 14, 2008.
Original Articles
Case 36-2007 A 31-Year-Old Woman with Rash, Fever, and Hypotension
Sabatine M. S., Poh K.-K., Mega J. L., Shepard J.-A. O., Stone J. R., Frosch M. P.
Extract |
Full Text |
PDF |
CME Exam
N Engl J Med 2007;
357:2167-2178, Nov 22, 2007.
Case Records of the Massachusetts General Hospital
Risk Alleles for Multiple Sclerosis Identified by a Genomewide Study
The International Multiple Sclerosis Genetics Consortium
Abstract |
FREE Full Text |
PDF
N Engl J Med 2007;
357:851-862, Aug 30, 2007;
published at www.nejm.org on Jul 29, 2007 (10.1056/NEJMoa073493).
Original Articles
Old Suspects Found Guilty The First Genome Profile of Multiple Sclerosis
Peltonen L.
Extract |
Full Text |
PDF
N Engl J Med 2007;
357:927-929, Aug 30, 2007;
published at www.nejm.org on Jul 29, 2007 (10.1056/NEJMe078147).
Editorials
Risk Alleles for Multiple Sclerosis Identified by a Genomewide Study
The International Multiple Sclerosis Genetics Consortium
Abstract |
FREE Full Text |
PDF
N Engl J Med 2007;
published at www.nejm.org on
Jul 29, 2007
(10.1056/NEJMoa073493).
Original Articles
Old Suspects Found Guilty The First Genome Profile of Multiple Sclerosis
Peltonen L.
Extract |
Full Text |
PDF
N Engl J Med 2007;
published at www.nejm.org on
Jul 29, 2007
(10.1056/NEJMe078147).
Editorials
Natural History of Multiple Sclerosis with Childhood Onset
Renoux C., Vukusic S., Mikaeloff Y., Edan G., Clanet M., Dubois B., Debouverie M., Brochet B., Lebrun-Frenay C., Pelletier J., Moreau T., Lubetzki C., Vermersch P., Roullet E., Magy L., Tardieu M., Suissa S., Confavreux C., the Adult Neurology Departments KIDMUS Study Group
Abstract |
FREE Full Text |
PDF
N Engl J Med 2007;
356:2603-2613, Jun 21, 2007.
Original Articles
Natalizumab for Multiple Sclerosis
Ransohoff R. M.
Extract |
Full Text |
PDF
N Engl J Med 2007;
356:2622-2629, Jun 21, 2007.
Clinical Therapeutics
Lack of Association between Antimyelin Antibodies and Progression to Multiple Sclerosis
Kuhle J., Pohl C., Mehling M., Edan G., Freedman M. S., Hartung H.-P., Polman C. H., Miller D. H., Montalban X., Barkhof F., Bauer L., Dahms S., Lindberg R., Kappos L., Sandbrink R.
Abstract |
FREE Full Text |
PDF
N Engl J Med 2007;
356:371-378, Jan 25, 2007.
Original Articles
Focus on Research: Fingolimod and Sphingosine-1-Phosphate Modifiers of Lymphocyte Migration
Massberg S., von Andrian U. H.
Extract |
Full Text |
PDF
N Engl J Med 2006;
355:1088-1091, Sep 14, 2006.
Perspective
Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis
Kappos L., Antel J., Comi G., Montalban X., O'Connor P., Polman C. H., Haas T., Korn A. A., Karlsson G., Radue E. W., the FTY720 D2201 Study Group
Abstract |
FREE Full Text |
PDF
N Engl J Med 2006;
355:1124-1140, Sep 14, 2006.
Original Articles
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Polman C. H., O'Connor P. W., Havrdova E., Hutchinson M., Kappos L., Miller D. H., Phillips J. T., Lublin F. D., Giovannoni G., Wajgt A., Toal M., Lynn F., Panzara M. A., Sandrock A. W., the AFFIRM Investigators
Abstract |
FREE Full Text |
PDF
N Engl J Med 2006;
354:899-910, Mar 2, 2006.
Original Articles
Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis
Rudick R. A., Stuart W. H., Calabresi P. A., Confavreux C., Galetta S. L., Radue E.-W., Lublin F. D., Weinstock-Guttman B., Wynn D. R., Lynn F., Panzara M. A., Sandrock A. W., the SENTINEL Investigators
Abstract |
FREE Full Text |
PDF
N Engl J Med 2006;
354:911-923, Mar 2, 2006.
Original Articles
Evaluation of Patients Treated with Natalizumab for Progressive Multifocal Leukoencephalopathy
Yousry T. A., Major E. O., Ryschkewitsch C., Fahle G., Fischer S., Hou J., Curfman B., Miszkiel K., Mueller-Lenke N., Sanchez E., Barkhof F., Radue E.-W., Jäger H. R., Clifford D. B.
Abstract |
FREE Full Text |
PDF
N Engl J Med 2006;
354:924-933, Mar 2, 2006.
Original Articles
Medical Progress: Multiple Sclerosis The Plaque and Its Pathogenesis
Frohman E. M., Racke M. K., Raine C. S.
Extract |
Full Text |
PDF
N Engl J Med 2006;
354:942-955, Mar 2, 2006.
Review Articles
Selective Treatment of Multiple Sclerosis
Ropper A. H.
Extract |
Full Text |
PDF
N Engl J Med 2006;
354:965-967, Mar 2, 2006.
Editorials
Brief Report:Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis
Kleinschmidt-DeMasters B.K., Tyler K. L.
Summary |
FREE Full Text |
PDF
N Engl J Med 2005;
353:369-374, Jul 28, 2005;
published at www.nejm.org on Jun 9, 2005 (10.1056/NEJMoa051782).
Original Articles
|